cancer drugs news from FiercePharma
News
Calls for price cuts on cancer meds
If the government says cancer drugs aren't worth the cost, then what? Ask drugmakers to cut their prices. After the U.K.'s National Institute for Health and Clinical Excellence rejected four Read more...
NICE rejects four cancer meds
The debate over costly oncology meds rages on in the U.K. as the National Institute for Health and Clinical Excellence rejected four high-tech drugs for advanced kidney cancer treatment: Read more...
Costs put cancer docs in financial bind
Pricey cancer meds aren't just putting the squeeze on patients and insurers. They're putting oncologists in a financial quandary as well. We got an inkling of this recently when the American Society Read more...
Is Avastin really worth the cost?
Is Avastin an object lesson in weighing the costs of an expensive drug against its benefits? Some experts think so, and the New York Times over the weekend took an extensive look at the controversy. Read more...
Breast-cancer uptake boosts Avastin sales
Avastin may have lost its chance to go on the U.K.'s National Health Service formulary, but it's still blowing past sales expectations. Wall Street analysts are saying that faster-than-expected Read more...
More NICE debate over cancer meds
It's not just Roche that refused to fork over cost-effectiveness info on its cancer med to the U.K.'s National Institution for Clinical Health and Excellence. So, too, has Merck Serono. Yesterday, Read more...
Costly cancer meds put NHS in quandary
The hand-wringing over costly cancer medicines in the U.K. is something of an object lesson, raising questions about medical care for the haves versus the have-nots, and about just how much money a Read more...
New drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
Get more cancer drugs coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets